Alternatives to Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a Biotechnology tool: biopharmaceutical company pioneering RNA interference (RNAi) therapeutics to treat rare and prevalent genetic diseases. Here are the 52 closest alternatives, compared on pricing, features and what real users say.
The 20 closest Biotechnology companies to Alnylam Pharmaceuticals
- GEGenSight BiologicsNot rated
Developing innovative gene therapies to preserve or restore vision in patients with retinal diseases.
Eleven TherapeuticsNot ratedIsraeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.
Avidity BiosciencesNot ratedClinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.
Arrakis TherapeuticsNot ratedArrakis Therapeutics is a biopharmaceutical company developing oral medicines that target RNA to treat a range of diseases. The company is based in Waltham, Mas
Moderna2.5 out of 5 (2)Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Kite PharmaNot ratedBiotechnology company developing and commercializing cell therapies for cancer treatment.
- JUJuno TherapeuticsNot rated
Biotechnology company focused on developing cancer immunotherapies.
CRISPR TherapeuticsNot ratedBiotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
Degron TherapeuticsNot ratedClinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Seaport TherapeuticsNot ratedDeveloping novel therapeutics to restore gut lymphatic function.
- CRCreate MedicinesNot rated
Developing in vivo immunotherapies for autoimmune diseases and cancer.
Supernus PharmaceuticalsNot ratedBiopharmaceutical company developing and commercializing CNS disease treatments.
CellCentricNot ratedA clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.
AdcendoNot ratedDeveloping first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.
InfinimmuneNot ratedDeveloping human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.
EnteromeNot ratedClinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
MironidNot ratedBiopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).
CelerionNot ratedA global leader in clinical pharmacology and bioanalytical sciences.
Spark TherapeuticsNot ratedA biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.
Precision BioSciencesNot ratedA clinical-stage biotechnology company developing in vivo gene editing therapies.
Showing the next 20 closest matches. See the rest on the Alnylam Pharmaceuticals profile.
Sponsored rows are paid and labelled. Advertise on this page
